JETIR.ORG ISSN: 2349-5162 | ESTD Year : 2014 | Monthly Issue
JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)
An International Scholarly Open Access, Peer-reviewed, Refereed Journal

BRONCHIAL ASTHMA

[1]Avinash,[2]Aanchal Chandel,[3]Dr.Neeraj Bhandari,[4]Aman Sharma
[1]Student,[2]Assistant Professor[3]Assistant Professor[4]Assistant Professor
Author

Avinash,Student of B.Pharmacy,

School of Pharmacy,Arni University

Kathgarh,Indora,Distt.Kangra H.P.Pincode 176401(India)

Abstract
Wheezing, briefness of breath, casket miserliness, and coughing are symptoms of bronchial asthma, a condition of the airways that causes swelling and narrowing. Children's asthma is influenced by a complex interplay of factors, including the severity of the condition, how the children respond to it, the effectiveness of therapy, social roles, and the social environment. Dust, animal dander, weather variations, pollution, mold, pollen, respiratory infections, stress, and tobacco smoking are the most frequent causes of bronchial asthma. Inflammation and airway remodeling, including goblet cell hyperplasia, subepithelial fibrosis, collagen deposition, mucosal gland hyperplasia, smooth muscle hypertrophy, and extracellular matrix alterations, are the primary pathophysiological features of asthma. When diagnosing asthma, spirometry measures lung function, and pulse oximetry tracks oxygen saturation, which quantifies the quantity of arterial hemoglobin that is used in conjunction with oxygen) to diagnose bronchial asthma. Restoring normal respiratory function while avoiding symptoms, exacerbations, or side effects is the aim of asthma treatment. The sympathomimetic medications known as beta 2 agonists cause "selective" activation of beta 2 adrenergic receptors, which facilitates bronchodilation and alleviates bronchospasm. It is necessary to increase the number of controller agents when short actin beta 2 agonists are used as a substitute five or more times per day. For oral asthma treatment, prednisone and prednisolone are the recommended glucocorticoids. Because methylxanthines can inhibit phosphodiesterase, which causes bronchodilatation, they are frequently used to treat asthma. When theophylline is first used orally, gastrointestinal side side goods similar nausea and puking might do. likewise, poisonous symptoms can develop into arrhythmia and tachycardia.
Keywords: Bronchial asthma; Diagnosis; Etiology; Pathophysiology; Management

Introduction

A habitual seditious illness of the respiratory galleries, bronchial asthma is caused by the release of several seditious intercessors by mast cells, eosinophils, and T lymphocytes. Respiratory symptoms, bronchial blockage, and hype rreactivity are all brought on by inflammation of the respiratory airways(1,2). The following four processes regard for the maturity of airway blockage in bronchial asthma cases i) the bronchial smooth muscle contracts; ii) the airway walls swell; iii) mucus entrapments the bronchioles; iv) the lungs suffer unrecoverable differences(also known as" revising")(3). A significant public health issue that affects numerous people of all periods is bronchial- 150million people suffer from asthma(4). Asthma frequence is frequently advanced in industrialized than in developing nations, and it's a major public health issue that affects people of all periods(5). habitual bronchial asthma is illustrated by mucus hypersecretion, reversible airway inhibition, airway hyperresponsiveness(AHR), and airway inflammation(6). The impact of asthma in children depends on complex commerce between complaint inflexibility, response of children towards complaint, treatment effectiveness, social places, and social terrain. Bronchial asthma, if a remains unbridled during

nonage leads to nonstop symptoms leading to limitations in physical conditioning and it can lead to development of habitual obstructive pulmonary complaint during the after times of life(7-9).



.

A T-Helper cell (Th)-2-profile inflammation of the airways in asthmatic patients is typified by an excess of mast cells, eosinophils, and Th2 lymphocytes. These inflammatory cells secrete mediators that cause mucus secretion, remodeling, and bronchoconstriction.

The Th2 cytokines Interleukin (IL) 4, IL-5, IL-9, and IL-13, Transforming Growth Factor (TGF)-beta, Granulocyte/Macrophage Colony Stimulating Factor (GM-CSF), lipid mediators, and histamine are among the inflammatory mediators that propel this process. TGF beta, IL-11, and IL-17 are a few of these mediators with strong remodelling abilities. It was recently proposed that histamine contributes to airway remodelling by promoting connective tissue growth and fibroblast proliferation.[10-13].

Etiology of Bronchial Asthma

The frequence of asthma has changed over time; while it's adding worldwide in low- to middle- income countries, it seems to have peaked in certain developed countries. It has been hypothesised that coitus hormones may be intertwined in the a etiology of colorful forms of asthma since boys are more prone than girls to develop asthma as kiddies. We do not know what creates the association between asthma and internal health. Because asthma causes inflammation or because it puts physical strain on the body, it's likely that internal health issues like depression are aggravated by asthma. The correlation between internal health and asthma may present difficulties because of common etiological factors similar exposure to secondary bank, smoking during gestation, and dysfunctional homes.(14) There are several different phenotypes associated with asthma, each with its own birth, donation, and pathophysiology. The linked phenotypes of asthma are associated with colorful threat factors, videlicet inheritable, environmental, and host variables. Despite being wide, a family history of asthma does n't guarantee the development of asthma(15). This knowledge has n't led to a generalized immunologic emphasis on asthma opinion and treatment. This review summarizes former epidemiologic substantiation relating IgE- intermediated events with asthma using literal data, skin testing, and more recent exploration using in vitro tests to look at new subject groups. It shows that numerous acute occurrences and up to 75 – 100 of cases of habitual asthma can have an mislike aetiology. thus, it's recommended to do down with the antiquated bracket of asthma into foreign and natural asthma and rather conduct a comprehensive analysis of antipathetic factors in nearly all cases with asthma(16).

The etiology of asthma is multifactorial, and its clinical picture varies greatly among cases. Some asthmatic cases demonstrate airway inflammation, generally involving neutrophils. Environmental substances that may beget asthma include inner allergens(e.g., dust diminutives, faves , and cockroaches), out-of-door allergens(e.g., pollen and dust), and sources of infection(e.g., bacteria, fungi, and spongers), occupational adulterants, or food complements. In terms of inheritable factors, a Genome Wide Association(GWA) study linked further than 100 genes as being significantly associated with the onset of bronchial asthma. In addition, mutations in the ORM1 gene have been revealed in studies on Single Nucleotide Polymorphisms(SNPs) to also be nearly related to the onset of asthma(17- 19).

Day-night pattern in bronchial asthma

This illness is a burden, and men are more affected than women, the elderly are more affected than the young, and the disease is worse at night than it is during the day or in the spring [20].

Mechanisms of nocturnal bronchial asthma

The complex mechanisms underlying nocturnal bronchial asthma include the daytime pro-inflammatory mediators released from mast and eosinophil cells in response to an antigen. These mediators are then released over several hours, leading to an exacerbation of inflammation by the end of the day, smooth muscle bronchospasm and contraction, and overstimulation of mucus glands, which causes mucus hypersecretion of the lung's small airways. Neuroendocrine and other significant high amplitude circadian rhythms, including those of the autonomic nervous system and the hypothalamic pituitary-adrenocortical (HPA) systems, can influence all of these activities [21].

Pathophysiology of Bronchial Asthma

The asthma phenotypes classified by GINA comprise of allergic, nonallergic, late-onset, asthma with fixed airflow limitation, and asthma associated with obesity[22]. The limited use of phenotypes stems from their classification based solely on observable characteristics, with no connection to the underlying disease process. Some of the recognized causes of chronic airway inflammation, which can lead to airway obstruction and hyperresponsiveness, include tobacco smoking, allergies, hormones, infections, cold air, obesity, exercise, systemic eosinophilia, and genetic abnormalities[23]. Inflammation and airway remodeling, encompassing goblet cell hyperplasia, subepithelial fibrosis, collagen deposition, mucosal gland hyperplasia, smooth muscle hypertrophy, and alterations in the extracellular matrix, are the primary pathophysiological features of asthma. These modifications may lead to immunological dysregulation, which in turn may cause hyperresponsiveness of the airways. Changes in transcription factors, inflammatorymediators, chemokines, cytokines.[24,25].



Clinical Manifestations of Bronchial Asthma

Dyspnea, or trouble breathing, fast breathing, tightness in the chest, wheezy chest, acute bronchoconstriction (instant), and croupy cough are among the symptoms of bronchial asthma. For those with the mildest type of the illness, bronchial asthma rarely poses a problem. For people who are predisposed to severe bronchial asthma, it can be a serious medical condition or even fatal. The hallmarks of bronchial asthma are reduced and aberrant airway diameter, increased airway hyperreactivity to antigens and other environmental stimuli, and persistent airway inflammation. There may be symptoms each time the airways are irritated[26].

Diagnosis of Bronchial Asthma

The following criteria were used to diagnose asthma: i) reversible airway obstruction that varied significantly, both spontaneously and in response to treatment; ii) intermittent wheezing (usually worsened on expiration and typically relieved by inhaled beta 2-agonists); iii) coughing (usually ineffective), shortness of breath (not always associated with wheezing), and chest tightness; iii) the possibility that the condition was brought on by a variety of factors, such as allergens, irritants, physical factors, emotions, occupational agents, food additives,

weather variations, endocrine factors, and upper respiratory tract viral infections; and iv) a decrease in Forced Expiratory Volume in one second (FEV1; absolute value and/or percentage of predicted value) and/or Peak Expiratory Flow (PEF) during the attack[27].

Differential Diagnosis of Bronchial Asthma

- The following entities should be considered in the differential diagnosis of bronchial asthma because of their frequency and clinical significance (28,30): It can be difficult to distinguish between asthma and COPD in up to 10% to 20% of cases.
- Chronic obstructive pulmonary disease (COPD)
- Hyperventilation
- Aspiration
- Laryngeal changes/vocal cord dysfunction
- Pneumothorax
- Cystic fibrosis (CF)
- Cardiac diseases, e.g., left heart failure
- Pulmonary embolism
- Gastroesophageal reflux disorder.
- In as many as 10% to 20% of cases, a clear-cut distinction between asthma and COPD cannot be drawn.

Treatment of Bronchial Asthma

There are currently a number of medications available to treat bronchial asthma, and selecting one involves taking into account factors that include knowledge of the fundamental pharmacological Principles. Asthma-related reversible airway obstruction is brought on by bronchospasm, mucous membrane oedema, and mucosal gland hypersecretion. Different drugs act selectively on these aspects, therefore identifying the dominant factor is crucial to a successful course of treatment. As a result, the inflammatory component of asthma usually determines its severity more so than bronchial muscle constriction. Additionally, bronchospasm can be partially treated with bronchodilators, but airway obstruction brought on by bronchial inflammation is primarily resistant to these treatments and can be treated with steroids[31].

In order to prevent exacerbations, which are sudden, progressive worsenings of asthma symptoms that frequently necessitate immediate medical attention and/or the use of oral steroid therapy, as well as to reduce the risk of mortality and morbidity, the primary goal of managing asthma is to achieve and maintain disease control. It has been demonstrated that consistent ICS treatment enhances lung function, reduces symptoms and exacerbations, and improves quality of life. The only treatment that should be combined with LABA administration is ICS therapy. [32,33]

Pharmacological Treatment of Bronchial Asthma

Anti-leukotrienes

Asthma is an inflammatory illness. An effective therapy intervention starts with the use of anti-inflammatory medicines.Currently, steroids are administered orally, parenterally, and aerosolically. Side effects and intrinsic administration problems are associated with corticosteroid therapy. Consequently, scientists are investigating a relatively new family of drugs called leukotriene modifiers, or ALT, LA. The ALT is a novel class of asthma-specific, anti-inflammatory drugs that specifically target certain mediators. The ALT show great promise as novel asthma therapies. The use of selective Cys LT receptor antagonists, such as Zafirlukast, Pranlukast, and Montelukast, as well as Zileuton, a direct inhibitor of 5-LO, has been found to be beneficial in the management of asthma and bronchoconstriction caused by exposure to allergens, exercise, aspirin, cold air, and inhaled LTs[34].

Allergy-specific immunotherapy (AIT)

In allergy-specific immunotherapy (AIT), the patient receives gradually higher doses of the pertinent allergens sublingually or subcutaneously until an effective dose is obtained that effectively establishes immunologic

tolerance to the allergen[35]. AIT is currently the gold standard for the treatment of allergic rhinitis. Allergy-induced rhinitis is more common in those with asthma.

On the other hand, direct bronchial allergen exposure increases nasal eosinophilic inflammation in asthmatics who do not have rhinitis. It is widely acknowledged that nasal allergy inflammation can exacerbate airway allergy inflammation and that the two can occur simultaneously. Treating allergic rhinitis reduces asthmatic aggravation, lowers AHR, and minimizes symptoms of asthma. We found that individuals with uncontrolled asthma are aware that therapy for rhinitis typically improves asthma symptoms, and that treatment for rhinitis typically makes asthma symptoms worse[36].

Probiotics used in the prevention and treatment of bronchial asthma

The Global Burden of Disease Study states that[37] Approximately 270 million persons worldwide suffered from asthma in 2019, based on an age-standardized prevalence of 341.5 cases per 100,000 people. In recent years, numerous environmental factors linked to the development of asthma have been found, despite the disease's complex origin[38-41]. Probiotics are also known to influence macrophages, Th17 cells, natural killer (NK) cells, and monocytes. In fact, strains of Lactobacillus used in commercial products have been shown to upregulate the expression of IL-6, IL-8, and tumor necrosis factor-alpha (TNF-α) in a human monocyte cell line, thereby facilitating an antimicrobial response [42]. Probiotics often promote host immunity by stimulating the release of IL-10 and interferon-gamma (INF-γ) [43,44]. Furthermore, Lactobac illaceae help the host absorb iron, calcium, and magnesium by biosynthesizing vitamins B12, B9, and B7 [45,46]. This study examines the most recent research on the effects of specific bacterial strains on bronchial asthma, as well as the role that probiotics play in asthma prevention and treatment. The sources of this research include a variety of animal models and clinical trials involving children. It also identifies the challenges associated with the homogeneity of existing data and suggests modifications that can be made to optimize the potential of probiotics in asthma therapy[47-49]. Patients with bronchial asthma experience excessive bronchoconstriction in response to stimuli, which manifests as episodes of shortness of breath followed by wheezing and coughing, especially during the night and early in the morning. In children with cough-variant asthma, an isolated cough may be the only symptom of the disease [50–52].

Probiotics used:-

1. Lactobacillus
2. Bifidobacterium
3. Streptococcus

Non-Pharmacological Treatment Of Bronchial Asthma

Eliminating allergies is a crucial part of non-pharmacological treatment, particularly for pets with fur or feathers. Regularly eating a balanced diet, quitting smoking, avoiding a sedentary lifestyle (which weakens the lungs), and avoiding obesity or weight loss (since obesity raises the body's inflammatory response) are all examples of lifestyle changes. It is not a good idea to restrict physical activity; instead, asthmatics should be encouraged to engage in physical activity. It is not a good idea to restrict physical activity; instead, asthmatics should be encouraged to engage in physical activity. Better self-management that results in better symptom control, fewer asthma attacks and emergency situations, and improvements in a number of other disease course parameters, such as days missed from work or school and hospital stays; physical training that reduces asthma symptoms, improves exercise tolerance, enhances quality of life, and lowers morbidity; respiratory therapy and physiotherapy (e.g., breathing techniques, pursed-lip breathing); quitting smoking (with medical and non-medical aids, if necessary); and psychosocial treatment approaches (family therapy).

Agents for Short-Term Management(Reliver)

Short acting beta 2 agonists (SABAs)

SABAs are thought of as agents that ease pain. Compared to oral delivery, inhalation therapy with a pMDI, DPI, and nebulizer exhibits an equivalent or even greater bronchodilator activity. Albuterol, bitolterol, pirbuterol, terbutaline, salbutamol, levalbuterol, and mesylate are a few examples of short-acting beta-2 agonists that can be inhaled. The sympathomimetic medications known as beta 2 agonists cause "selective" activation of beta 2 adrenergic receptors, which facilitates bronchodilation and alleviates bronchospasm. They also boost ciliary motility and inhibit the release of histamines in the lungs. For the treatment of asthma, beta2-selective drugs have supplanted older, less selective sympathomimetics (such as isoproterenol and

epinephrine). All patients with asthma use these drugs. Beta2 agonists, given by inhalation, are the most effective drugs available for relieving acute bronchospasm and preventing Exercise-Induced Bronchospasm (EIB)[53].

Oral corticosteroids

Corticosteroids used orally For significant exacerbations, a SABA and an oral corticosteroid must be used for approximately a week. When asthma symptoms are treated for a brief period of time (often less than a week) with an oral corticosteroid dose (about 0.5 mg/kg of prednisolone), acute exacerbations are avoided, ER visits and hospital admissions are decreased, and everyday life is improved. The recommended glucocorticoids for oral treatment of asthma are prednisone and prednisolone. Adults typically take 30 to 40 mg twice daily for 5 to 7 days as part of acute treatment. Alternate-day dose is advised for long-term treatment. . The use of oral glucocorticoids is limited to individuals with severe asthma. These medications are only recommended when symptoms are uncontrollable due to their potential for toxicity.

Short-acting muscarinic receptor antagonists (SAMAs)

SAMAs improve pulmonary function for moderate to severe exacerbations, lower the rate of hospital admissions, and have additive effects with beta 2 agonists. SABAs are available for acute exacerbations when SABAs are not available, despite the fact that SAMAs have a later onset of bronchodilatory effects than SABAs [55,56].

Long-acting b2 agonists (LABAs)

Drugs that act as β2-adrenergic agonists To treat bronchial asthma, doctors frequently give β2-agonist drugs. In order to improve airway quality and airflow rate and facilitate breathing, they attach to cell membranes and trigger adenylate cyclase, which relaxes the smooth muscle of the small airways. Airway inflammation may potentially be modulated by β2-agonists. For individuals who have frequent episodes, long-acting inhaled beta 2 agonists (LABAs) can be taken for long-term management. Dosing is done according to a set schedule rather than on an as-needed basis. For long-term control, LABAs are not the best option and shouldn't be used exclusively.The duration of action of early-generation conventional aerosol bronchodilator drugs is usually restricted to no more than [57,58]. Side effects of inhaled beta2 agonists: These drugs are generally well tolerated. Although they are rarely severe, systemic symptoms (tachycardia, angina, and tremor) can happen. Excessive oral preparation dosage can result in tachydysrhythmias and angina pectoris by stimulating cardiac beta1 receptors. By stimulating beta2 receptors in skeletal muscle, patients should be told to report any chest pain, changes in heart rate, or tremor. Lowering the dosage or letting it happen naturally can lessen tremor.

Sustained-release theophylline

Methylxanthines can inhibit Phosphodiesterase (PDE), which results in bronchodilatation, they are frequently used to treat asthma. In addition to bronchodilation, methylxanthines also exhibit immunomodulatory, bronchoprotective, and anti-inflammatory properties. These medications have a small margin of safety, necessitating close blood level monitoring, which calls for therapeutic drug monitoring. It was discovered that methylxanthines did not significantly improve the effects of inhaled beta-agonists. has a limited therapeutic range, therefore dosage needs to be carefully managed. Theophylline helps lessen the frequency and intensity of asthma attacks when taken regularly. Theophylline may be most suited for people who have nocturnal episodes due to its long-lasting effects.In emergency situations, intravenous theophylline has been used. Theophylline used to be the first-line treatment for asthma and almost all people with persistent[59,60,61].

Leukotriene receptor antagonists (LTRAs)

As an adjuvant treatment for asthma, montelukast, an antagonist of the Cysteinyl Leukotriene 1 (CysLT1) receptor, is frequently utilized. Additionally, it was just authorized to treat exercise-induced asthma and allergic rhinitis. In a clinical investigation, montelukast-treated asthmatic patients with nasal polyposis saw improvements in clinical asthma scores of 60% to 90% and a 70% reduction in nasal symptoms. In asthmatic individuals, montelukast reduces sputum eosinophils following an allergen challenge. CysLT antagonists have anti-inflammatory properties, but they may also be crucial in the pathophysiology of airway remodeling. In sensitized mice, it has been demonstrated that montelukast effectively inhibits ovalbumin-induced subepithelial fibrosis, mucus gland hyperplasia, and airway smooth muscle hyperplasia.

After just eight weeks of montelukast medication, a recent study found that the number of lymphocytes and myofibroblasts in the airways of asthmatic individuals had decreased. Antileukotrienes may stop airway remodeling at the level of goblet and smooth muscle cell hyperplasia, as well as subepithelial fibrosis, according to data from these animal and human investigations. Long-term research is necessary to validate the therapeutic results of CysLT1 receptor antagonists' antiremodelling impact in asthmatic patients, though.[62,63,64].

Anti-allergics other than LTRAs

In mild to moderately severe asthma, Allergen-Specific Subcutaneous Immunotherapy (SCIT), commonly known as "desensitization," has been demonstrated to lower medication use and bronchial hyperreactivity when compared to a placebo; however, it has no effect on pulmonary function values (evidence level A). Younger patients are primarily affected by this statement. In elderly individuals with long-standing asthma whose symptoms occur independently of allergen exposure and for whom anti-inflammatory medication has not been as successful, SCIT has a significantly decreased chance of effectiveness. Patients whose FEV1 readings are less than 70% and whose pulmonary function is consistently compromised should not undergo SCIT. Only a doctor with expertise in allergology should administer specific immunotherapy. It should be viewed as an adjunct to successful anti-asthmatic medication rather than as a replacement for it[65].

Anti-IgE antibody: Anti-IgE antibody

Omalizumab is an antihuman IgE monoclonal antibody that has been humanized. The following asthmatic individuals can have omalizumab in Japan: (i) people who, after receiving large dosages of ICSs and many controller agents, nonetheless experience unstable asthmatic symptoms; (ii) those who test positive for persistent inhaled antigens, like dust from the home; (iii) The dosage conversion chart is used to establish the dosage and frequency of administration based on the patient's weight and serum IgE level (30–1500) IU/ML. Even when a high dose of ICS is used to treat patients with poor asthma control, omalizumab has the following effects: (i) it keeps asthma attacks from getting worse; (ii) it lessens the frequency of symptoms; (iii) it enhances quality of life; (iv) it lowers the frequency of ER visits and hospital stays. FEV1 and PEF readings are slightly improved by omalizumab. Its efficacy has only been verified in patients receiving ICS/LABA who are poorly managed. When treating severe chronic asthma, omalizumab should be utilized as a therapeutic agent in step 4. The therapeutic results can be thoroughly assessed 16 weeks post-administration, at which point it should be decided if the treatment should be continued [66,67].

Mast cell stablizers

Nedocromil and Cromolyn Inhalational medications that reduce bronchial inflammation include cromolyn and nedocromil. In patients with mild to moderate asthma, both medications are utilized for prophylaxis rather than immediate relief. There are fewer anti-inflammatory effects than with glucocorticoids. Cromolyn: Although it is not helpful in stopping an ongoing asthma attack, Cromolyn is a very safe and effective medication for asthma prevention. Cromolyn reduces inflammation in the lungs and is administered by inhalation; it is not a bronchodilator.The medication works in part by keeping mast cells' cytoplasmic membrane stable, which stops histamine and other mediators from escaping. Cromolyn also suppresses macrophages, eosinophils, and other inflammatory cells.

Conclusion

With the involvement of mast cells, eosinophils, and T lymphocytes, as well as the release of several inflammatory mediators, bronchial asthma is a chronic inflammatory illness of the respiratory passages. Although the exact cause of bronchial asthma is still unknown, it is generally accepted that both hereditary and environmental factors play a role in its pathogenesis. Treatment for asthma involves preventing antigen exposure, lowering bronchial inflammation and hyperactivity, and widening the lung's constricted airways. The best medications for treating acute bronchospasm and avoiding exercise-induced bronchospasm (EIB) are beta2 agonists, which are administered via inhalation. Because glucocorticoids control inflammation, they lessen the symptoms of asthma. Glucocorticoids have specific anti-inflammatory actions, such as: i) a reduction in the production and release of inflammatory mediators, such as histamine, prostaglandins, and leukotrienes; ii) Reduced infiltration and activity of inflammatory cells (such as leukocytes and eosinophils);

iii) lessened edema of the airway mucosa (due to a decrease in vascular permeability); bronchial asthma is a chronic inflammatory illness of the glands.

Reference

[1]Moskvin Sergey Vladimirovich and Khadartsev Aleksandr A. "Methods of effective low-level laser therapy in the treatment of patients with bronchial asthma," BioMedicine. 2020; 10: 1-20.
[2]The global asthma report. Auckland, New Zealand: Global Asthma Network. 2018.
[3]Deutsches Ärzteblatt Internationa, Dtsch Arztebl Int. 2008; 105: 385-394.
[4]Gaude GS, Hattiholi J, Chaudhury A. Role of health education and self-action plan in improving the drug compliance in bronchial asthma. J Fam Med Primary Care. 2014; 3: 33-38.
[5]Wang R and Lin J. Analysis of the Mechanism of Zhichuanling Oral Liquid in Treating Bronchial Asthma Based on Network Pharmacology. Evidence Based Complementary and Alternative Medicine. 2020; 2020: 10.
[6] Bochner BS, UndemBJ,Lichtenstein LM. Immunological aspects of allergic asthma. Annu Rev Immunol 1994;12:295–335.
[7] Gajanan G, Padbidri VS, Chaudhury A. Assessment of Knowledge and Attitude of Parents Towards the Allergy and Bronchial Asthma in Their Children. Inter. J. Med. Public Health. 2016; 6: 121-125.
[8] Suarez-Varela MM, Garcia de Andoin N, Batlles-Garrido J, et al. Geographic variance in the prevalence of asthma symptoms in Spanish children and adolescents.International study of Asthma and Allergies in Childhood (ISSAC) Phase 3, Spain]. Arch Bronchoneumol. 2005; 41: 659-666.
[9] Anjan kumar DS, Adepu R, Parthasarathi G, Mahesh PA. Impact of community pharmacist provided patient education in asthma patients on treatment outcomes-A study. Indian J Pharm Educ Res. 2009; 43: 125-133.
[10] M Ichinose, et al. Japanese guidelines for adult asthma. Allergology International. 2017; 66: 163-189.
[11] Bergeron C, et al. Airway remodelling in asthma: From benchside to clinical practice. Can Respir J. 2010; 17; e85-93.
[12] Kunzmann S, Schmidt-Weber C, Zingg JM, et al. Connective tissue growth factor expression is regulated by histamine in lung fibroblasts: Potential role of histamine in airway remodeling. J Allergy Clin Immunol. 2007; 119: 1398 1407.
[13] Westergren-Thorsson G, Chakir J, Lafreniere-Allard MJ, Boulet LP, Tremblay GM. Correlation between airway responsiveness and proteoglycan production by bronchial fibroblasts from normal and asthmatic subjects. Int J Biochem Cell Biol. 2002; 34: 1256-1267.
[14] Zock JP, Heinrich J, Jarvis D, et al. Distribution and determinants of house dust mite allergens in Europe: the European Community Respiratory Health Survey II. J Allergy Clin Immunol 2006;118:682-90.
[15] Burke W, Fesinmeyer M, Reed K, et al. Family history as a predictor of asthma risk. Am J Prev Med 2003;24:160-9.
[16]Stern J, Pier J, Litonjua AA. Asthma epidemiology and risk factors. Semi Immunopatho. 2020;42(1):5–15.
[17] Xu P, Wang L, Chen D, Feng M, Lu Y, Chen R, et al. The application of proteomics in the diagnosis and treatment of bronchial asthma. Ann Transl Med. 2020; 8: 132.
[18]Rhee CK. Nanotechnology as a savior in asthma management. Ann Transl Med. 2019; 7: 517.
[19] Burgstaller G, Oehrle B, Gerckens M, et al. The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. Eur Respir J. 2017; 50: 1601805.
[20] MH Smolensky, et al. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Advanced Drug Delivery Reviews. 2007; 59: 852-882.
[21]MH Smolensky, et al. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Advanced Drug Delivery Reviews. 2007; 59: 852-882.
[22]GINA. Pocket Guide for asthma management and prevention for adults and children. 2018 [23]Gans MD, Gavrilova T. Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes. Paedi Respir Revi. 2020;36:118–127.
[24]Valero A, Ribó P, Maíz L, et al. Asthma patient satisfaction with different dry powder inhalers. Expert Rev Respir Med. 2019; 13: 133-138.
[25]Lee Y, Hwang YH, Kim KJ, et al. Proteomic and transcriptomic analysis of lung tissue in OVA-challenged mice. Arch Pharm Res. 2018; 41: 87-10
[26]MH Smolensky, et al. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Advanced Drug Delivery Reviews. 2007; 59: 852-882.
[27]S Ragab, et al. Treatment of chronic rhinosinusitis and its effects on asthma. Eur Respir J. 2006; 28: 68-74.
[28] Ärztliches Zentrum für Qualität in der Medizin. Nationale Versorgun Leitlinie Asthma bronchiale (www.asthma.versorgungsleitlinien.de) *Dtsch Arztebl.* 2005;102(40):A 2734–A 2734.

[29]Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. *Eur Respir J.* 2008;31:143–178
[30]Buhl R, Berdel D, Criee C-P, Gillissen A, Kardos P, Kroegel C, et al. Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. *Pneumologie.* 2006;60:139–183.
[31]Norn, S. & Skov, P. Stahl; Patliophysiologic mechanisms in asthma. Molecular and pharmacological aspects. Scand. J. Respir. Dis. Suppl. 103, 25-32, 1979.
[32]Lougheed MD, Lemière C, Dell SD Et al. Canadian Thoracic Society asthma management continuum: 2010 consensus summary for children six years of age and over, and adults. Can Respir J. 2010;17(1):15-24
[33]Lougheed MD, Lemiere C, Ducharme FM, et al. Canadian Thoracic Society Asthma Clinical Assembly. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Can Respir J. 2012;19(2):127–64.
[34]Gupta G, Jatana SK, Wilson CG. Anti-leukotrienes in Childhood Asthma. Medical Journal Armed Forces India. 2002;58(3):242–246.
[35]Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol. 2010;125(Suppl 2):S306–S313.
[36]Nakagome K, Nagata M. Allergen immunotherapy in asthma. Pathogens. 2021;10(11):1406.
[37]Wang Z, Li Y, Gao Y, Fu Y, Lin J, Lei X, et al. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the global burden of Disease Study 2019. Respir Res. 2023;24(1):169.
[38]Global Initiative for Asthma. Global Strategy for Asthma Man agement and Prevention, 2023.
[39]Ye L, Pan J, Pasha MA, Shen X, D'Souza SS, Fung ITH, et al. Mucosal-associated invariant T cells restrict allergic airway inflam mation. J Allergy Clin Immunol. 2020;145(5):1469–e14734.
[40]Ye L, Pan J, Liang M, Pasha MA, Shen X, D'Souza SS, et al. A critical role for c-Myc in group 2 innate lymphoid cell activation. Allergy. 2020;75(4):841–52.
[41]Murrison LB, Brandt EB, Myers JB, Hershey GKK. Environ mental exposures and mechanisms in allergy and asthma devel opment. J Clin Invest. 2019;129(4):1504–15.
[42]Balzaretti S, Taverniti V, Guglielmetti S, Fiore W, Minuzzo M, Ngo HN, et al. A Novel Rhamnose-Rich Hetero-Exopoly saccharide isolated from Lactobacillus paracasei DG acti vates THP-1 human monocytic cells. Appl Environ Microbiol. 2017;83(3):e02702–16
[43]Lin EK, Chang WW, Jhong JH, Tsai WH, Chou CH, Wang IJ. Lacticaseibacillus paracasei GM-080 ameliorates allergic Airway inflammation in children with allergic rhinitis: from an animal model to a Double-Blind, randomized, placebo-controlled trial. Cells. 2023;12(5):768.
[44]Jia DJ, Wang QW, Hu YY, He JM, Ge QW, Qi YD et al. Lacto bacillus johnsonii alleviates colitis by TLR1/2-STAT3 mediated CD206(+) macrophages(IL-10) activation. Gut Microbes. 2022 Jan-Dec;14(1):2145843.
[45]Yoshii K, Hosomi K, Sawane K, Kunisawa J. Metabolism of dietary and microbial vitamin B Family in the regulation of host immunity. Front Nutr. 2019;6:48.
[46]Dargahi N, Johnson J, Donkor O, Vasiljevic T, Apostolopoulos V. Immunomodulatory effects of probiotics: can they be used to treat allergies and autoimmune diseases? Maturitas. 2019;119:25–38.
[47]Malmström K, Pelkonen AS, Mäkelä MJ. Remodeling, inflam mation and airway responsiveness in early childhood asthma. Curr Opin Allergy Clin Immunol. 2013;13(2):203–10.
[48]Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res. 2010;690(1–2):24–39.
[49]Qin Z, Chen Y, Wang Y, Xu Y, Liu T, Mu Q, et al. Immu nometabolism in the pathogenesis of asthma. Immunology. 2024;171(1):1–17.
[50]Bergeron C, Boulet LP. Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest. 2006;129(4):1068–87.
[51]Kaufman G. Asthma: pathophysiology, diagnosis and manage ment. Nurs Stand. 2011;26(5):48–57.
[52]M Ichinose, et al. Japanese guidelines for adult asthma. Allergology International. 2017; 66: 163-189.
[53]M Ichinose, et al. Japanese guidelines for adult asthma. Allergology International. 2017; 66: 163-189.
[54]Lazarus SC. Clinical practice. Emergency treatment of asthma. N Engl J Med. 2010; 363: 755- 764. 55. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with metaanalysis. Thorax. 2005
[55]MH Smolensky, et al. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Advanced Drug Delivery Reviews. 2007; 59: 852-882.
[56] K Maneechotesuwan, S Essilfie-Quaye, S Meah, C Kelly, SA Kharitonov, IM Adcock, et al. Formoterol attenuates neurophilic airway inflammation in asthma, Chest. 2005; 128: 1936-1942.

[57] MH Smolensky, et al. Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. Advanced Drug Delivery Reviews. 2007; 59: 852-882
[58]K Maneechotesuwan, S Essilfie-Quaye, S Meah, C Kelly, SA Kharitonov, IM Adcock, et al. Formoterol attenuates neurophilic airway inflammation in asthma, Chest. 2005; 128: 1936-1942.
[59]Sami Manzoor, et al. To Compare the Efficacy of Doxophylline from Theophylline in Asthma. Journal of Clinical and Diagnostic Research. 2015; 9: FC05-FC08.
[60]Nair P, Milan SJ, Row BH. Addition of intravenous aminophyllineto inhaled beta agonists in adults with acute asthma (Review). Cochrane Database Syst Rev. 2012; 12: 2742.
[61] K Maneechotesuwan, S Essilfie-Quaye, S Meah, C Kelly, SA Kharitonov, IM Adcock, et al. Formoterol attenuates neurophilic airway inflammation in asthma, Chest. 2005; 128: 1936-1942
[62]Bergeron C, et al. Airway remodelling in asthma: From benchside to clinical practice. Can Respir J. 2010; 17; e85-93.
[63]Henderson WR Jr, Tang LO, Chu SJ, et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002; 165: 108-116.
[64]Kelly MM, Chakir J, Vethanayagam D, et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest. 2006; 130: 741-753
[65]Kelly MM, Chakir J, Vethanayagam D, et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest. 2006; 130: 741-753.
[66]B Ding and M Small. “Disease burden of mild asthma: findings from a crosssectional real-world survey,” Advances in, erapy. 2017; 34: 1109-1127.
[67]Buhl R, Berdel D, Criee C-P, Gillissen A, Kardos P, Kroegel C, et al. Leitlinie zur Diagnostik und Therapie von Patienten mit Asthma. Pneumologie. 2006; 60: 139-183.